FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial
News
The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA’s approval of Immunic’s investigational new drug ... Read more